Non-alcoholic fatty liver disease (NAFLD) is characterized by the accumulation of lipids in macrovesicular hepatic vesicles in about ≥5% of hepatocytes in patients who do not have a secondary cause for steatosis, such as alcohol consumption, hepatitis C, medications, protein malnutrition, or parenteral nutrition. The current research was designed to evaluate the association between non-alcoholic fatty liver disease and chronic kidney disease in patients with NAFLD. This study was conducted from December 2023 until March 2024 at the following main locations: AL-Nasriya Technical Hospital, Nasiriya Governorate, Iraq; Mohammed AL-Mousawi Children′s Hospital, Nasiriya Governorate, Iraq; and AL-Imam AL-Hussain Hospital, Nasiriya Governorate, Iraq. The samples consisted of sixty patients diagnosed with NAFLD and twenty-eight patients without NAFLD. Patient samples included 30 males aged between 28 and 75 years and 30 females aged between 20 and 70 years. The control group’s ages ranged between 28 and 65 years. The creatinine test results showed a non-significant increase in patients with NAFLD compared to the control group; in contrast, the glomerular filtration rate (GFR) decreased significantly in the patients group compared to the control. The results also showed significant decreases in FABP-4, PAI-1, and TNF-α levels in patients with NAFLD compared to the control group. Based on the results of the current study, FABP-4 and PAI-1 are considered excellent markers for predicting chronic kidney disease (CKD), and TNF-α can also be considered a reliable marker for predicting CKD.
T. G. Cotter and M. Rinella, "Nonalcoholic fatty liver disease 2020: the state of the disease," Gastroenterology, vol. 158, no. 7, pp. 1851-1864, 2020.
V. W.-S. Wong, M. Ekstedt, G. L.-H. Wong, and H. Hagström, "Changing epidemiology, global trends and implications for outcomes of NAFLD," Journal of Hepatology, vol. 79, no. 3, pp. 842-852, 2023.
S. Della Torre, "Non-alcoholic fatty liver disease as a canonical example of metabolic inflammatory-based liver disease showing a sex-specific prevalence: relevance of estrogen signaling," Frontiers in Endocrinology, vol. 11, p. 572490, 2020.
L. Rinaldi et al., "Mechanisms of non-alcoholic fatty liver disease in the metabolic syndrome. A narrative review," Antioxidants, vol. 10, no. 2, p. 270, 2021.
P. Vancells Lujan, E. Vinas Esmel, and E. Sacanella Meseguer, "Overview of non-alcoholic fatty liver disease (NAFLD) and the role of sugary food consumption and other dietary components in its development," Nutrients, vol. 13, no. 5, p. 1442, 2021.
M. De Vries, J. Westerink, K. H. Kaasjager, and H. W. De Valk, "Prevalence of nonalcoholic fatty liver disease (NAFLD) in patients with type 1 diabetes mellitus: a systematic review and meta-analysis," The Journal of Clinical Endocrinology & Metabolism, vol. 105, no. 12, pp. 3842-3853, 2020.
K. Ozaki, K. Kozaka, Y. Kosaka, H. Kimura, and T. Gabata, "Morphometric changes and imaging findings of diffuse liver disease in relation to intrahepatic hemodynamics," Japanese Journal of Radiology, vol. 38, pp. 833-852, 2020.
X. Cai et al., "Non-alcoholic fatty liver disease is associated with increased risk of chronic kidney disease," Therapeutic Advances in Chronic Disease, vol. 12, 2021.
H. R. Al-Sabah, A. C. Y. Al-Fatlawi, and Q. M. Al-Obaidy, "Neutrophil gelatinase-associated lipocalin (NGAL) and cystatin C: potential biomarkers for early prediction of acute kidney injury in pediatric male patients," IJApSc, vol. 1, no. 1, pp. 24-35, Jun. 2024, doi: 10.69923/IJAS.2024.010103.
L. Q. Abdulhameed, A. A. Sultan, and Z. M. M. AL-Mahdawi, "Homocysteine: A recent potential risk factor for type 2 diabetes mellitus patients in Diyala Province," in AIP Conference Proceedings, vol. 2593, no. 1, May 2023. AIP Publishing.
A. Venniyoor, "PTEN: a thrifty gene that causes disease in times of plenty?," Frontiers in Nutrition, vol. 7, p. 81, 2020.
N. Ebert et al., "Assessment of kidney function: clinical indications for measured GFR," Clinical Kidney Journal, vol. 14, no. 8, pp. 1861-1870, 2021.
S. Kiapidou, C. Liava, M. Kalogirou, E. Akriviadis, and E. Sinakos, "Chronic kidney disease in patients with non-alcoholic fatty liver disease: What the Hepatologist should know?," Annals of Hepatology, vol. 19, no. 2, pp. 134-144, 2020.
A. S. Henkel, S. S. Khan, S. Olivares, T. Miyata, and D. E. Vaughan, "Inhibition of plasminogen activator inhibitor 1 attenuates hepatic steatosis but does not prevent progressive nonalcoholic steatohepatitis in mice," Hepatology Communications, vol. 2, no. 12, pp. 1479-1492, 2018.
A. Gidaro et al., "Prothrombotic and inflammatory markers in elderly patients with non-alcoholic hepatic liver disease before and after weight loss: a pilot study," Journal of Clinical Medicine, vol. 10, no. 21, p. 4906, 2021.
I. D. Vachliotis, I. Valsamidis, and S. A. Polyzos, "Tumor necrosis factor-alpha and adiponectin in nonalcoholic fatty liver disease-associated hepatocellular carcinoma," Cancers, vol. 15, no. 21, p. 5306, 2023.
P. L. Eriksen, K. L. Thomsen, M. Sørensen, H. Vilstrup, and A.-M. Hvas, "Impaired fibrinolysis without hypercoagulability characterises patients with non-alcoholic fatty liver disease," Thrombosis Research, vol. 213, pp. 9-15, 2022.
R. Rodríguez-Calvo et al., "Relationship between fatty acid binding protein 4 and liver fat in individuals at increased cardiometabolic risk," Frontiers in Physiology, vol. 12, p. 781789, 2021.
A. Han, "Association of Cardiovascular Risk Factors and Metabolic Syndrome with non-alcoholic and alcoholic fatty liver disease: a retrospective analysis," BMC Endocrine Disorders, vol. 21, p. 91, 2021.
·
This work is licensed under a
Creative Commons Attribution-ShareAlike 4.0 International License
